As of Jan 17
| -0.0188 / -3.31%|
The 2 analysts offering 12-month price forecasts for Rosetta Genomics Ltd have a median target of 2.75, with a high estimate of 3.50 and a low estimate of 2.00. The median estimate represents a +400.36% increase from the last price of 0.55.
The current consensus among 2 polled investment analysts is to Buy stock in Rosetta Genomics Ltd. This rating has held steady since January, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.